Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
World Vitiligo Map
Your guide to the vitiligo community worldwide. Use the selector to filter by patient support groups, specialists, research centers, clinical trial locations, or World Vitiligo Day events.
Directory Information & Disclaimer
This free public directory gathers information from public sources to help connect our global community. Medical professionals and organizations listed are independent and not affiliated with or endorsed by the Vitiligo Research Foundation (VRF), and no fees are accepted for listings.
Because clinics, support groups, and specialists move or update their services over time, some information may occasionally become outdated. As a result, VRF cannot guarantee the complete accuracy or usefulness of listed third-party resources.
Help Us Keep the Map Accurate
Do you need to add a listing, update outdated details, or request a removal? Please reach out to us using the feedback form on our Contact Us page.
Search Map
78 records found for “NCT06804811” · show all
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Sanos Clinic, Herlev, 02730, Denmark
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Centre Hospitalier Universitaire (Chu) de Bordeaux - Groupe Hospitalier Pellegrin, Bordeaux, 33076, France
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Centre Hospitalier Intercommunal de Creteil, Créteil, 75571, France
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Hospices Civils de Lyon (Hcl) - Hopital Edouard Herriot (Heh), Lyon, 69003, France
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hopital Hotel Dieu, Nantes, 44093, France
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Hopital Universitaire Necker Enfants Malades, Paris, 75015, France
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Chu Nancy, Vandœuvre-lès-Nancy, 54500, France
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Charite - Universitaetsmedizin Berlin - Campus Charite Mitte (Ccm), Berlin, 10117, Germany
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Hautklinik Universitatsklinikum Erlangen, Erlangen, 91054, Germany
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11University Medical Center Schleswig-Holstein, Kiel, 24105, Germany
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Universitaetsklinikum Leipzig, Leipzig, 04103, Germany
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii, Mainz, 55131, Germany
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Klinikum Rechts Der Isar Der Technischen Universitaet Muenchen (Hopital Rechts Der Isar), München, 81675, Germany
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11University Hospital Muenster, Münster, 48149, Germany
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Clinexpert, Budapest, 01033, Hungary
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11University of Szeged, Szeged, 06720, Hungary
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Azienda Ospedaliera Spedali Civili Di Brescia-Universita Degli Studi Di Brescia, Brescia, 25123, Italy
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Azienda Ospedaliero-Universitaria Policlinico Vittorio Emanuele Ospedale Gaspare Rodolico Di Catania, Catania, 95123, Italy
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Uoc Dermatologia Ospedale Maggiore Policlinico, Fondazione Irccs Ca' Granda, Milan, 20122, Italy
1.855.463.3463
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Phase: PHASE3
Intervention: Drug: Ruxolitinib Cream; Drug: Vehicle Cream
Status: Open now
Organizer: Incyte Corporation
Trial page: https://vrfoundation.org/trials/ruxolitinib-cream-for-children-ages-6-to-11Azienda Ospedaliero Universitaria Federico Ii Di Napoli, Naples, 80131, Italy
1.855.463.3463
FAQOther Questions
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
- Does halo nevi affect vitiligo development?
Halo nevi (also known as Sutton's nevi) are characterized by a mole that's surrounded by a ring of depigmented or lighter skin. While both halo nevi and vitiligo involve the des...
- Is vitiligo contagious?
Vitiligo is not contagious. This means it cannot be spread from person to person through physical contact, sharing personal items, or any other means of transmission. Vitiligo i...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.